Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on April 2023

Classification of products:

Status	Description
GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
RED	Red-Hospital initiation and continuation only
GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
PURPLE	To be supplied from the appropriate commissioned provider.
NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil				
2) New Requests				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Dexcom One Real-time Continuous Glucose Monitoring (rt-CGM)	√ AMB 1 AMB 2			Requested as option in children & adults with Type 1 or Type 2 adults with diabetes on multiple daily insulin injections and including pregnant women, as outlined in NICE guidance https://www.nice.org.uk/guidance/ng28 https://www.nice.org.uk/guidance/ng17 https://www.nice.org.uk/guidance/ng18 https://www.nice.org.uk/guidance/ng3 Decision: recommended as AMBER 1/Amber 2 for both type 1 and type 2 diabetes dependant on pathway subject to ICB approval of the overall CGM policy and an educational programme being in place for primary care.
3) New formulations & extensions to use				
Nil this month				
4) Products considered by NICE				
TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis	RED			The formulary will reflect the TAG – ICS is the responsible commissioner. 30-day NICE TA published 1st February 2023.
TA862: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA863: Somatrogon for treating growth disturbance in children and young people aged 3 years and over	RED			The formulary will reflect the TAG – ICS is the responsible commissioner. 30-day NICE TA published 1st February 2023.
TA864: Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA865: Nivolumab with fluoropyrimidine and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA866: Regorafenib for previously treated metastatic colorectal cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA867: Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA869: Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA870: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA872: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
HST22: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
5) Appeals against earlier decisions by the APC				
None				
6) Miscellaneous formulary decisions by the APC				
None				

The following guidelines were presented to and approved at the April 2023 meeting of the APC:

- Distress in dementia

The following shared care guidelines were presented to and approved at the April 2023 meeting of the APC:

- Nil this month

Other documents presented to and approved at the April 2023 meeting of the APC:

- Anticoagulation for non-valvular atrial fibrillation (NVAF) following NHSE DOAC commissioning recommendation